---
title: "Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299797255.md"
description: "Oppenheimer reiterated an Outperform rating on Tyra Biosciences with a $40 price target, implying 55.9% upside from the September 21 close of $25.65. The firm highlighted Tyra's strong pipeline of FGFR-targeted therapies and its innovative SNAP platform for precision medicine as key drivers for potential growth in the oncology market."
datetime: "2026-09-22T17:10:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299797255.md)
  - [en](https://longbridge.com/en/news/299797255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299797255.md)
generator: "portal-rs"
---

# Oppenheimer reiterates Outperform rating on Tyra Biosciences, $40 price target

Oppenheimer reiterated their Outperform rating on Tyra Biosciences's stock with a price target of $40.00.

The price target implies an upside of 55.9% from the Sep 21 close of $25.65.

**Key takeaways from the analyst note**

**Strong Pipeline of FGFR-targeted Therapies**: Tyra Biosciences is advancing a compelling pipeline of clinical-stage drug candidates that specifically target FGFR3, FGFR4/3, and FGFR1/2/3, which are designed to address the limitations of existing FGFR inhibitors. This positions the company favorably in the oncology market, with the potential for high efficacy and improved safety profiles.

**Innovative Precision Medicine Platform**: The company's proprietary SNAP platform allows for rapid, data-driven drug design, enhancing the likelihood of developing effective therapies. This innovative approach not only accelerates the drug development process but also optimizes candidate selection, making Tyra Biosciences a potentially attractive investment in the biotechnology sector.

Explore more price target data and ratings for Tyra Biosciences on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)

## Related News & Research

- [TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY | TYRA Stock News](https://longbridge.com/en/news/287215316.md)
- [Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead](https://longbridge.com/en/news/298782816.md)
- [Peter Schiff Warns Trump’s ‘Booming’ Stock Market Boast Is a Mirage: 479 Stocks Hit 52-Week Lows on Wednesday, While Only 60 Set Highs](https://longbridge.com/en/news/301958076.md)
- [Why Is Rocket Lab Stock Plunging in Premarket Today? What This Top Analyst Sees Next](https://longbridge.com/en/news/301962657.md)
- [CRWV vs. NBIS: Which Neocloud Stock Offers More Upside as the AI Sell-Off Continues?](https://longbridge.com/en/news/301970902.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**